Saniona completes SAN2465 tox, CMC studies, targets IND filing by end — October 2026
Saniona completed toxicology and CMC work for SAN2465, clearing the package needed to support an IND filing. IND submission to the FDA is targeted by end-October 2026, setting up first-in-human dosing plans. Planned Phase 1 trial targets safety, tolerability, pharmacokinetics in healthy volunteers, with biomarker reado